Long-term care pharmacy leaders call for COVID-19 relief from Congress
McKnight’s Senior Living
Kimberly Bonvissuto– July 14, 2020
Leaders from 12 of the nation’s largest long-term care pharmacies sent a letter to leaders in Congress on Friday asking for $350 million in financial relief to meet challenges presented by the COVID-19 pandemic.
Members of the Senior Care Pharmacy Coalition, which represents 75% of the long-term care pharmacy sector, cited significant revenue losses and higher costs due to the pandemic in serving assisted living communities, nursing homes and other communal settings where older adults live.
“Due to the pandemic, LTC pharmacy revenues have dropped 25% while costs increased 6% from March to May,” the letter reads, citing unplanned costs for additional personal protective equipment, employee support and medication supplies, as well as higher delivery expenses. “Without financial relief, residents in nursing homes and assisted living facilities may face interruptions in access to essential, life-saving medications.”
The requested $350 million in relief represents 2% of long-term care pharmacy annual patient care revenues of $17.5 billion, which is the benchmark relief percentage the U.S. Department of Health and Human Services established for other providers, the organization said.
SCPC President and CEO Alan Rosenbloom said that policymakers have provided $4.9 billion in COVID-19 Medicare relief funds for nursing homes and $15 billion in funds for Medicaid providers, and that HHS is working on relief for assisted living providers, but long-term care pharmacies — which he called the “essential behind-the-scenes partner” — largely have been ignored.
He also said HHS created new obstacles to relief for LTC pharmacies in June by excluding prescription sales from patient revenues and disproportionately limited relief compared with other provider types.
Long-term care pharmacies “cannot be silent about the outsized impacts the pandemic has had on our sector and our need for immediate relief to fulfill this nation’s promise to our most vulnerable citizens,” the letter said.
About 2 million Americans in long-term care facilities rely on long-term care pharmacies to manage and deliver 12 to 13 different medications daily to each resident, according to SCPC.
“The financial situation for long-term care pharmacies mirrors the financial situation for nursing homes and assisted living facilities,” Rosenbloom said. “Congress must address this issue promptly to ensure LTC pharmacies have access to the relief they need. The absence of this timely, consistent pharmacy support from LTC pharmacies would make the dire circumstances LTC facilities continue to work through much worse.”
Companies represented on the letter were PharmcareUSA, Guardian Pharmacy Services, PharMerica, NHS Management, Consonus, Forum Extended Care Services, M Chest Institutional Pharmacy Group, HealthDirect Institutional Pharmacy Services, PharmScript, Remedi SeniorCare and PCA Pharmacy.
Senior Care Pharmacy Coalition Provides Comments on Improving Care for Dually Eligible Enrollees
The Senior Care Pharmacy Coalition (SCPC), the only Washington-based organization exclusively representing the interests of long-term care (LTC) pharmacies, has responded to a Request for Information issued by a bipartisan group of Senators led by Senator Bill Cassidy (R-LA) regarding policy recommendations to improve care for enrollees dually eligible for Medicare and Medicaid programs (dual eligibles) and substantially reduce the amount of money both programs otherwise would expect to spend over time.
Let’s improve LTC pharmacy policy in the home
Across all cultures and generations, caregivers have long served an integral role supporting the health of family members’ or friends in need of long-term care (LTC). In many cases, these caregivers are unpaid individuals without formal training — often a spouse, partner, family member, friend or neighbor.
Rosenbloom: Curb PBMs’ power
Despite the purported value of pharmacy benefit managers (PBMs), drug prices remain unaffordable for many Americans (“Prescription drug pricing reform must rein in pharmacy benefit managers,” Web, Oct. 18). As middlemen between the manufacturers, pharmacies and consumers, PBMs are notorious for abusive business practices that impact both patients’ wallets and their access to prescription drugs, while gouging unaffiliated pharmacies.
Stay in the Know
Get the latest news and updates on issues impacting the long-term pharmacy community.